Clinical Trials Logo

Filter by:
NCT ID: NCT02500004 Completed - Neoplasms Clinical Trials

Brown Adipose Tissue Activity and Energy Metabolism in Cachexia

BAT-Cachexia
Start date: June 2015
Phase: N/A
Study type: Interventional

To study BAT activity and energy metabolism in patients with cachexia induced by cancer or chronic disease.

NCT ID: NCT02499471 Completed - Obesity Clinical Trials

Brown Adipose Tissue Activity and Thyroid Hormone

Start date: March 2012
Phase: N/A
Study type: Interventional

Rationale: During the last decades, research in possible therapies for existing obesity and developmental factors causing obesity has explosively increased. Recently renewed interest aroused for a tissue playing a possible role in both development and therapy for obesity: brown adipose tissue (BAT). To define the relation between BAT and thyroid hormone, the investigators set up the following research protocol. In this protocol BAT activity will be determined in subjects that underwent thyroidectomy for well-differentiated thyroid carcinoma. Objective: To study the effect of thyroid hormone and thyroid-stimulating hormone on brown adipose tissue activity. Study design: Determine BAT activity after thyroidectomy in well-differentiated thyroid carcinoma patients. Study population: Patients that underwent thyroidectomy for well-differentiated thyroid carcinoma, male and female, aged 18-65 years. Intervention: FDG-PET-CT-imaging ([18F]fluorodeoxyglucose positron-emission-tomography computed-tomography) of BAT activity will be performed under cold stimulation twice. For patients clinically withdrawn from thyroid hormone suppletion, the first occasion will be in a hypothyroid state within 4-6 weeks after thyroidectomy and the second measurement will take place in a euthyroid state 4 months after the start of thyroid hormone treatment. For patients receiving recombinant-thyroid-stimulating-hormone injections, the first occasion will be shortly after the injection in a state of high thyroid-stimulating hormone levels. The second measurement will be in a euthyroid state 4 months after the injection. Main study parameters/endpoints: The main endpoint of this study is the effect of thyroid hormone and thyroid-stimulating hormone on BAT activity in kBq (kilobecquerel) and SUV (standard uptake value). Secondary endpoints are the effects of thyroid hormone and thyroid-stimulating hormone on energy metabolism, body core temperature, skin surface temperatures and skin perfusion. Nature and extent of the burden and risks associated with participation, benefit and group relatedness: The absorbed radiation dose from the FDG PET-CT scan after administration of 74 MBq (megabecquerel) of 18F-FDG is 2.8 mSv (miliSievert).

NCT ID: NCT02499367 Active, not recruiting - Breast Cancer Clinical Trials

Nivolumab After Induction Treatment in Triple-negative Breast Cancer (TNBC) Patients

TONIC
Start date: August 2015
Phase: Phase 2
Study type: Interventional

This is a single center non-blinded randomized non-comparative phase II trial. The first stage of the trial consists of five arms ( with induction treatment followed by nivolumab, 1 with no induction treatment before nivolumab). For the second stage, the number of arms will be reduced based on the results obtained in the first stage.

NCT ID: NCT02498106 Completed - Clinical trials for Psychiatric Hospitalization

Diet and Aggression: Reducing Aggression Among Chronic Psychiatric Inpatients Through Dietary Supplementation

Start date: May 2015
Phase: N/A
Study type: Interventional

The overall goal of this study is to investigate whether the daily administration of multivitamins, minerals and n-3 fatty acids will reduce aggression in long-term psychiatric inpatients and will thereby reduce costs of care.

NCT ID: NCT02497950 Completed - Heart Failure Clinical Trials

HeartMate 3 ELEVATEā„¢ Registry

ELEVATEā„¢
Start date: October 13, 2015
Phase:
Study type: Observational [Patient Registry]

Evaluate real-world experience of HeartMate 3 (HM3) in post-approval setting.

NCT ID: NCT02497664 Completed - Lung Cancer Clinical Trials

Optimizing (Breathing) Techniques for Radiotherapy of Esophageal and Lung Carcinomas

ABC
Start date: January 2016
Phase: N/A
Study type: Interventional

Neo-adjuvant chemoradiotherapy (neo-CRT) is increasingly applied in the curative treatment of esophageal cancer, with the aim to downstage the tumor, to increase the rate of radical resections, and consequently to improve the survival rates. Due to improved survival, it will become increasingly important to minimize the radiation-induced toxicity among long-term survivors. In the management of locally advanced non small cell lung cancer (NSCLC), radiotherapy is the standard treatment modality. However, the dose that can be safely applied to the tumour is limited by the risk of cardiac and pulmonary complications, which even led to decreased survival in a randomised study, when a higher tumor dose was administered [1]. Radiation induced pulmonary and cardiac toxicity are the most important late side effects after thoracic radiotherapy [2-4]. The aim of this study is to reduce the radiation dose of heart (and lungs) in order to reduce the toxicity risk. In recent years, the active breathing control (ABC) technique has been introduced in the radiotherapy for left sided breast cancer patients, to minimize the radiation dose to the heart. These patients are irradiated in the inspiration phase, in which the distance between the heart and the breast is largest, while the lungs extend. Breath hold might also be beneficial for radiotherapy of esophageal and lung tumors. For these patients the expiratory phase might theoretically be more beneficial to reduce the heart dose. However, the inspiration phase might be better for the dose to the lungs, which consequently allows cardiac dose reduction.

NCT ID: NCT02497599 Recruiting - Clinical trials for Carcinoma, Renal Cell

Intraoperative Dual-modality Imaging in Renal Cell Carcinoma

Start date: June 2015
Phase: Phase 1
Study type: Interventional

Intraoperative tumor localization and resection can be enhanced using intraoperative fluorescence imaging and radiodetection. Girentuximab specifically recognizes carbonic anhydrase IX expressed on > 95% of renal cell carcinoma (RCC). Therefore Indium-111-DOTA-girentuximab-IRDye800CW is a perfect dual-labeled antibody for dual-modality image-guided surgery in RCC. The aim of this study is to assess the feasibility and safety of intraoperative dual-modality imaging with Indium-111-DOTA-girentuximab-IRDye800CW in renal cell carcinoma patients.

NCT ID: NCT02497469 Completed - Colitis, Ulcerative Clinical Trials

An Efficacy and Safety Study of Vedolizumab Intravenous (IV) Compared to Adalimumab Subcutaneous (SC) in Participants With Ulcerative Colitis

Start date: June 29, 2015
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of vedolizumab intravenous (IV) treatment compared to adalimumab subcutaneous (SC) treatment over a 52-week treatment period.

NCT ID: NCT02496767 Completed - Clinical trials for Amyotrophic Lateral Sclerosis

Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year

VITALITY-ALS
Start date: September 3, 2015
Phase: Phase 3
Study type: Interventional

This study assessed the effect of tirasemtiv versus placebo on respiratory function in patients with ALS.

NCT ID: NCT02496741 Completed - Glioma Clinical Trials

Metformin And Chloroquine in IDH1/2-mutated Solid Tumors

MACIST
Start date: November 2015
Phase: Phase 1/Phase 2
Study type: Interventional

This phase Ib, open-label, single-center, non-randomized clinical trial will evaluate the toxicity and efficacy of metformin and chloroquine in isocitrate dehydrogenase 1/2-mutated (IDH1/2MT) patients with a glioma, intrahepatic cholangiocarcinoma or chondrosarcoma.